An Open-Label Extension (OLE), Long-term Safety and Tolerability Study of Plecanatide in Patients With Chronic Idiopathic Constipation
Phase of Trial: Phase III
Latest Information Update: 04 Jul 2019
Price : $35 *
At a glance
- Drugs Plecanatide (Primary)
- Indications Constipation
- Focus Adverse reactions; Registrational
- Sponsors Synergy Pharmaceuticals
- 19 Jan 2017 According to a Synergy Pharmaceuticals media release, the U.S. Food and Drug Administration (FDA) has approved TRULANCE™ (plecanatide) for the treatment of adults with chronic idiopathic constipation (CIC).
- 17 Oct 2016 According to a Synergy Pharmaceuticals media release, new long-term safety data was presented at the American College of Gastroenterology (ACG) annual scientific meeting.
- 17 Oct 2016 Long term results published in a Synergy Pharmaceuticals media release.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History